Question 1

What is Immunomic Therapeutics, Inc.?

Accepted Answer

Immunomic Therapeutics, Inc. (ITI) is a privately-held, clinical stage biotechnology company that is pioneering the study of nucleic acid immunotherapy platforms.

Question 2

What is the focus of Immunomic Therapeutics?

Accepted Answer

Immunomic Therapeutics is primarily focused on applying its UNITE® platform to oncology, where it could potentially have broad applications. The company has built a pipeline leveraging UNITE® with programs in oncology, animal health, infectious disease, and allergy.

Question 3

What is the UNITE® platform?

Accepted Answer

Immunomic Therapeutics' investigational UNITE® platform, Universal Intracellular Targeted Expression, leverages the ability to engineer chimeric proteins, directing antigen presenting cells to present antigens to the immune system through a targeted pathway and driving a robust immune response.

Question 4

Is Immunomic Therapeutics a public or private company?

Accepted Answer

Immunomic Therapeutics is a privately-held company.

Immunomic Therapeutics

Company Overview

Company Name

Address

Website

Phone

Employees

Established

About Immunomic Therapeutics

Frequently Asked Questions about Immunomic Therapeutics

What is Immunomic Therapeutics, Inc.?

What is the focus of Immunomic Therapeutics?

What is the UNITE® platform?

Is Immunomic Therapeutics a public or private company?

Technologies Used

Social Profiles

Key Decision Makers